Quantification of antigen-reactive T cells by a modified ELISPOT assay based on freshly isolated blood dendritic cells

Journal of Clinical Laboratory Analysis

Volumn 16, Issue 1, 2002, Pages 30-36

  Schmitz, M ^a   Rohayem, J ^a   Paul, R ^a   Weigle, B ^a   Stein, A ^b   Rieber, E P ^a,c  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Dendritic cells; ELISPOT assay; Immune monitoring; Interferon gamma; T cells

Indexed keywords

EPITOPE; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DIAGNOSTIC ACCURACY; ENZYME ASSAY; ENZYME LINKED IMMUNOSPOT; HUMAN; HUMAN CELL; IMMUNE RESPONSE; QUANTITATIVE ASSAY;

DENDRITIC CELLS; HUMANS; IMMUNOENZYME TECHNIQUES; INTERFERON TYPE II; MELANOMA; MONOPHENOL MONOOXYGENASE; T-LYMPHOCYTES;

EID: 0036145713     PISSN: 08878013     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcla.2072     Document Type: Article

References (41)

1. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
2. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
3. Antigen recognition by class-I restricted T lymphocytes
4. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin-2
5. The role of CD4+ T cell responses in antitumor immunity
6. HLA-peptide tetrameric complexes
7. Phenotypic analysis of antigen-specific T lymphocytes
8. Single cell analyses of cytokine production
9. Analysis of Th1 and Th2 cells in murine gut-associated tissues. Frequencies of CD4+ and CD8+ T cells that secrete IFN-gamma and IL-5
10. In vivo dynamics of anti-viral CD8 T cell responses to different epitopes. An evaluation of bystander activation in primary and secondary responses to viral infection
11. Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells
12. Insect cells as HLA-restricted antigen-presenting cells for the interferon-gamma ELISPOT assay
13. The dendritic cell system and its role in immunogenicity
14. Dendritic cells: Unique leukocyte populations which control the primary immune response
15. Dendritic cells and the control of immunity
16. Immunobiology of dendritic cells
17. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
18. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines
19. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells
20. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
21. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
22. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
23. Treatment of solid tumours in children with tumour-lysate pulsed dendritic cells
24. A novel dendritic cell population in human blood: One-step immunomagnetic isolation by a specific mAb (M-DC8) and in vitro priming of cytotoxic T lymphocytes
25. The minimum peptide epitope from the influenza virus matrix protein. Extra and intracellular loading of HLA-A2
26. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins
27. Long-term culture and fine specificity of human cytotoxic T lymphocyte clones reactive with human immunodeficiency virus type 1
28. Evaluation of the interferon-gamma ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood
29. Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens
30. The use of computer-assisted video image analysis for the quantification of CD8+ T lymphocytes producing tumor necrosis factor alpha spots in response to peptide antigens
31. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53
32. IFN-gamma secretion following stimulation with total tumor peptides from autologous human tumors
33. A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA-class-I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients
34. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4+T lymphocytes of patients with NY-ESO1-expressing melanoma
35. Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer
36. Presentation of Epstein-Barr virus latency antigens to CD8+, interferon-gamma-secreting, T lymphocytes
37. Cytolytic T cell reactivity against melanoma-associated differentiation antigens in peripheral blood of melanoma patients and healthy individuals
38. Help for cytotoxic T cell responses is mediated by CD40 signalling
39. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell
40. T help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions
41. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4+ T lymphocytes